ANGION BIOMEDICA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Angion Biomedica Corp - ANGNPRNewsWire • 03/10/23
ANGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Angion Biomedica Corp. Is Fair to ShareholdersBusiness Wire • 02/27/23
ANGION BIOMEDICA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Angion Biomedica Corp - ANGNBusiness Wire • 01/19/23
STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Angion Biomedica Corp. - ANGNPRNewsWire • 01/18/23
Shareholder Alert: Ademi LLP investigates whether Angion Biomedica Corp. has entered into a Fair Transaction with ElicioPRNewsWire • 01/18/23
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Angion Biomedica Corp. MergerNewsfile Corp • 01/17/23
Angion Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/15/22
Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder ValueGlobeNewsWire • 07/25/22
Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney DiseaseGlobeNewsWire • 06/29/22
Angion Provides Corporate Update and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/16/22
Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary FibrosisGlobeNewsWire • 05/16/22
Angion Provides Corporate Update and Reports Full Year 2021 Financial ResultsGlobeNewsWire • 03/30/22
Angion Provides Corporate Update and Announces Participation in Upcoming Investor ConferenceGlobeNewsWire • 01/04/22
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injuryBusiness Wire • 12/10/21
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney InjuryGlobeNewsWire • 12/09/21